Results 281 to 290 of about 1,270,348 (335)

How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency. [PDF]

open access: yesHematol Rep
Tama-Shekan S   +3 more
europepmc   +1 more source

Elevated serum aminotransferases in an infant with failure to thrive: A clinicopathological case report

open access: yes
JPGN Reports, EarlyView.
Jamie M. Klapp   +4 more
wiley   +1 more source

Targeting pyruvate kinase M2 for the treatment of kidney disease. [PDF]

open access: yesFront Pharmacol
Chen DQ, Han J, Liu H, Feng K, Li P.
europepmc   +1 more source

LEAF PYRUVATE KINASE

open access: yes, 1982
Yamanoto, Tan, Bassham, James A.
openaire   +1 more source

pyruvate kinase deficiency

CABI Compendium, 2022
This datasheet on pyruvate kinase deficiency covers Identity, Hosts/Species Affected.

semanticscholar   +1 more source

Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.

Biochimica et biophysica acta. Reviews on cancer, 2021
Pyruvate is irreversibly decarboxylated to acetyl coenzyme A by mitochondrial pyruvate dehydrogenase complex (PDC). Decarboxylation of pyruvate is considered a crucial step in cell metabolism and energetics.
Saleha Anwar   +4 more
semanticscholar   +1 more source

Pyruvate kinase deficiency

Clinical Biochemistry, 1990
Pyruvate kinase (PK) deficiency was initially described by Valentine et al. in 1961. Since then, more than 300 cases have been described, including 65 in Japan. PK deficiency is the most common hereditary nonspherocytic hemolytic anemia among several red cell enzyme defects of the Embden-Meyerhof glycolytic pathway.
S, Miwa, H, Fujii
openaire   +4 more sources

Home - About - Disclaimer - Privacy